title: HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives.
abstract: (1,1-Dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives have been investigated as potential anti-HCV drugs. Their synthesis, HCV NS5B polymerase inhibition, and replicon activity are discussed.
authors.affiliation: Discovery Research, InterMune, Inc., Brisbane, CA 94005, USA. gyiwang@yahoo.com
authors.forename: Guangyi
authors.initials: G
authors.lastname: Wang
authors.forename: Huoxing
authors.initials: H
authors.lastname: Lei
authors.forename: Xiaofang
authors.initials: X
authors.lastname: Wang
authors.forename: Debasis
authors.initials: D
authors.lastname: Das
authors.forename: Jian
authors.initials: J
authors.lastname: Hong
authors.forename: Colin H
authors.initials: CH
authors.lastname: Mackinnon
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Coulter
authors.forename: Christian A G N
authors.initials: CA
authors.lastname: Montalbetti
authors.forename: Richard
authors.initials: R
authors.lastname: Mears
authors.forename: Xinjie
authors.initials: X
authors.lastname: Gai
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Bailey
authors.forename: Donald
authors.initials: D
authors.lastname: Ruhrmund
authors.forename: Lisa
authors.initials: L
authors.lastname: Hooi
authors.forename: Shawn
authors.initials: S
authors.lastname: Misialek
authors.forename: P T Ravi
authors.initials: PT
authors.lastname: Rajagopalan
authors.forename: Robert K Y
authors.initials: RK
authors.lastname: Cheng
authors.forename: John J
authors.initials: JJ
authors.lastname: Barker
authors.forename: Brunella
authors.initials: B
authors.lastname: Felicetti
authors.forename: Dorian L
authors.initials: DL
authors.lastname: Schönfeld
authors.forename: Antitsa
authors.initials: A
authors.lastname: Stoycheva
authors.forename: Brad O
authors.initials: BO
authors.lastname: Buckman
authors.forename: Karl
authors.initials: K
authors.lastname: Kossen
authors.forename: Scott D
authors.initials: SD
authors.lastname: Seiwert
authors.forename: Leonid
authors.initials: L
authors.lastname: Beigelman
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D001393:Azoles / Q000138:chemical synthesis* / Q000494:pharmacology; D001581:Benzothiadiazines / Q000138:chemical synthesis* / Q000494:pharmacology; D002626:Chemistry, Pharmaceutical / Q000379:methods; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D016174:Hepacivirus / Q000378:metabolism; D006526:Hepatitis C / Q000188:drug therapy*; D066298:In Vitro Techniques; D020128:Inhibitory Concentration 50; D009682:Magnetic Resonance Spectroscopy; D008956:Models, Chemical; D015394:Molecular Structure; D011725:Pyridines / Q000138:chemical synthesis* / Q000494:pharmacology; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000494:pharmacology; D013329:Structure-Activity Relationship; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D001393:Azoles; D001581:Benzothiadiazines; D004791:Enzyme Inhibitors; D011725:Pyridines; D011743:Pyrimidines; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase